Citations (16)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (5)
Clemens Warnke, Heinz Wiendl, Hans-Peter Hartung, Olaf Stüve & Bernd C Kieseier. (2010) Identification of targets and new developments in the treatment of multiple sclerosis – focus on cladribine. Drug Design, Development and Therapy 4, pages 117-126.
Read now
Read now
Hans-Peter Hartung. (2009) High-dose, high-frequency recombinant interferon beta-1a in the treatment of multiple sclerosis. Expert Opinion on Pharmacotherapy 10:2, pages 291-309.
Read now
Read now
Douglas S. Goodin, Louis D. Biermann, Saeed Bohlega, Alexey Boiko, Michel Chofflon, Souheil Gebeily, Riadh Gouider, Eva Havrdova, Gabor Jakab, Rana Karabudak, Dimitrios Karussis, Ariel Miller, Hossein Pakdaman, Krzysztof Selmaj & Mohammad Sharief. (2007) Integrating an evidence-based assessment of benefit and risk in disease-modifying treatment of multiple sclerosis. Current Medical Research and Opinion 23:11, pages 2823-2832.
Read now
Read now
Lizheng Shi, Meredith Hodges, Nicole Yurgin & Kristina S Boye. (2007) Impact of dose frequency on compliance and health outcomes: a literature review (1966–2006). Expert Review of Pharmacoeconomics & Outcomes Research 7:2, pages 187-202.
Read now
Read now
Magnhild Sandberg-Wollheim. (2005) Interferon-β1a treatment for multiple sclerosis. Expert Review of Neurotherapeutics 5:1, pages 25-34.
Read now
Read now
Articles from other publishers (11)
Meheroz H. Rabadi & Christopher E. Aston. (2016) Effect of Chronic Medical Conditions in Veterans with Multiple Sclerosis on Long-Term Disability. Medical Science Monitor 22, pages 2768-2774.
Crossref
Crossref
Clare Fraser & Gordon T. Plant. 2011. Neuroinflammation. Neuroinflammation
253
276
.
C. Warnke, V.I. Leussink, B.C. Kieseier & H.-P. Hartung. (2010) Interferon β bei Multipler SkleroseInterferon β for multiple sclerosis. Der Nervenarzt 81:12, pages 1476-1482.
Crossref
Crossref
Ruth Ann Marrie & Ralph I Horwitz. (2010) Emerging effects of comorbidities on multiple sclerosis. The Lancet Neurology 9:8, pages 820-828.
Crossref
Crossref
C. PENA-ROSSI, S. SCHREIBER, G. GOLUBOVIC, A. MERTZ-NIELSEN, J. PANES, D. RACHMILEWITZ, M. J. SHIEH, V. I. SIMANENKOV, D. STANTON & H. GRAFFNER. (2008) Clinical trial: a multicentre, randomized, double-blind, placebo-controlled, dose-finding, phase II study of subcutaneous interferon-β-1a in moderately active ulcerative colitis. Alimentary Pharmacology & Therapeutics 28:6, pages 758-767.
Crossref
Crossref
Gavin Giovannoni, Olga Barbarash, Florence Casset-Semanaz, Amer Jaber, John King, Luanne Metz, Gabriel Pardo, James Simsarian, Per Soelberg Sørensen & Bettina Stubinski. (2007) Immunogenicity and tolerability of an investigational formulation of interferon-β1a: 24- and 48-week interim analyses of a 2-year, single-arm, historically controlled, phase IIIb study in adults with multiple sclerosis. Clinical Therapeutics 29:6, pages 1128-1145.
Crossref
Crossref
Pierre Miossec. 2007. Cytokines in Human Health. Cytokines in Human Health
233
257
.
D. Karussis, L. D. Biermann, S. Bohlega, A. Boiko, M. Chofflon, F. Fazekas, M. Freedman, S. Gebeily, R. Gouider, E. Havrdova, G. Jakab, R. Karabudak & A. Miller. (2006) A recommended treatment algorithm in relapsing multiple sclerosis: report of an international consensus meeting. European Journal of Neurology 13:1, pages 61-71.
Crossref
Crossref
R. A. MarrieG. CutterT. TyryO. HadjimichaelD. CampagnoloT. Vollmer. (2005) Changes in the ascertainment of multiple sclerosis. Neurology 65:7, pages 1066-1070.
Crossref
Crossref
Giancarlo Comi & Massimo Filippi. (2005) Clinical trials in multiple sclerosis: methodological issues. Current Opinion in Neurology 18:3, pages 245-252.
Crossref
Crossref
Pierre Miossec. 2005. Molecular Autoimmunity. Molecular Autoimmunity
329
345
.